Randomized Controlled Trial of Sirolimus for Renal Transplant Recipients at High Risk for Nonmelanoma Skin Cancer - Medscape News

Sirolimus has antineoplastic effects and may reduce skin cancer rates in kidney transplant patients. This prospective, multicenter, randomized, open-label, controlled trial randomized 86 kidney transplant recipients (≥1 year posttransplant ...

BK virus nephropathy in simultaneous pancreas kidney transplant: a potentially preventable cause of kidney allograft loss - Doctors Guide

All patients underwent rabbit anti-thymocyte globulin (rATG) induction and were maintained on tacrolimus/sirolimus or mycophenolate. The incidence of BKVN was 4.4%. BKVN was diagnosed at a median of 11 months; mean serum creatinine 2.1 mg/dL and ...

Post-SES implantation, statins prevent late revascularization - medicalxpress.com

(HealthDay) -- For patients who undergo sirolimus-eluting stent (SES) implantation, use of statin therapy is associated with a reduced risk of late target lesion revascularization (TLR), according to a study published in the May 15 issue of The ...

Svelte Medical Systems Announces Final Patient Treated in the DIRECT Drug-Eluting Stent Study - Business Wire

DIRECT is a First-In-Man, multi-center clinical study designed to assess the feasibility of Svelte’s novel ‘All-In-One’ system which combines a thin-strut cobalt chromium stent with a fully bio-absorbable drug carrier and the well-studied sirolimus ...

OrbusNeich’s Combo Dual Therapy Stent Continues to Show Promise in Clinical Trial - Medagadget.com

The randomized REMEDEE trial (Randomized Evaluation of an abluMinal sirolimus coatED bio- Engineered stEnt) found that the Combo Dual Therapy stent was non-inferior to the TAXUS Liberté paclitaxel-eluting stent based on in-stent late lumen ...

Early Coronary Artery Healing Advantage of OrbusNeich's Combo Dual Therapy Stent™ Compared to the TAXUS® … - Yahoo Finance

"The Combo Stent is the only technology that combines the value of endothelial progenitor cell capture to promote vessel healing with an abluminal sirolimus drug elution to limit neointimal proliferation," said Stephen M. Rowland, Ph.D., vice ...

Canada Pharmacies Anticipate New anti-rejection Drugs for Kidney Transplant Patients - PR-USA.net

Rapamune (Active ingredient: Sirolimus) is another immunosuppressive agent that joined the existing range of anti-rejection drugs used for preventing the kidney allograft rejection. More than 65,000 kidney transplants are done annually, allover the world.

Svelte completes enrollment in DIRECT drug-eluting stent study - News-Medical.Net

multi-center clinical study designed to assess the feasibility of Svelte's novel 'All-In-One' system which combines a thin-strut cobalt chromium stent with a fully bio-absorbable drug carrier and the well-studied sirolimus (rapamycin ...

Cordis Medical Device Company Intelligence Report - new company profile report - Transworld News

In 2003, the FDA approved the Cypher sirolimus-eluting coronary stent, the first combination drug-device product intended to help reduce restenosis, or "reclogging", of a treated coronary artery. Cordis signalled its commitment to continue stent innovation ...

BIOTRONIK's Bioabsorbable Magnesium Scaffold Continues to Show Strong Results at 12 Months With Uncompromised Device Usability - Boston Globe

The company has announced next-generation platforms under development using the BIOlute(R) coating from the Orsiro hybrid drug-eluting stent featuring sirolimus as the active compound. About BIOTRONIK SE & Co. KG As one of the world's leading ...